Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Beatriz Lapa
Observed names:
B. Lapa,
Beatriz Santos Lapa,
Lapa, Beatriz Santos
Institutions:
Centro de Investigação em Meio Ambiente Genética e Oncobiologia,
Centro de Inovação em Biomedicina e Biotecnologia,
University of Coimbra
Observed institutions:
Centro de Investigação em Meio Ambiente Genética e Oncobiologia,
Centro de Inovação em Biomedicina e Biotecnologia,
University of Coimbra
ORCID:
0000-0002-0455-4970
Observed ORCID:
0000-0002-0455-4970
OpenAlex ID:
A5086571032
Works
18
Awards
2
Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target
2020
·
Beatriz Lapa
, Ana Cristina Gonçalves
, et al.
·
Medical Oncology
·
47
Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells
2022
·
Maria Inês Costa
, Beatriz Santos Lapa
, et al.
·
International Journal of Molecular Sciences
·
17
PDF
Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation
2022
·
Joana Jorge
, Nisa Magalhães
, et al.
·
Biomedicines
·
15
PDF
AZD-7648, a DNA-PK Inhibitor, Induces DNA Damage, Apoptosis, and Cell Cycle Arrest in Chronic and Acute Myeloid Leukemia Cells
2023
·
Beatriz Santos Lapa
, Maria Inês Costa
, et al.
·
International Journal of Molecular Sciences
·
12
PDF
Altered cell cycle regulation in the development of resistance
2024
·
Raquel Alves
, Joana Jorge
, et al.
·
Elsevier eBooks
·
3
Non-coding RNAs: Therapeutic Implications in Cancers
2026
·
Raquel Alves
, Joana Jorge
, et al.
·
Cancer drug discovery and develogment/Cancer drug discovery and development
Pb1822: Inhibition of the Dna Damage Response: a Possible New Route in Acute Myeloblastic Leukemia Treatment
2023
·
Beatriz Lapa
, Maria Inês Costa
, et al.
·
HemaSphere
Pb1719: Niraparib in B-cell Lymphoid Malignancies: Exploring Synthetic Lethality as Target for Therapy
2023
·
Beatriz Lapa
, Ana Patrícia Portelinha
, et al.
·
HemaSphere
Pb1908: Nrf2 Inhibition in Combination With Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia– an in Vitro Study
2023
·
Joana Jorge
, Beatriz Constantino
, et al.
·
HemaSphere
P841: Molecular Mechanisms of Resistance to Immunomodulators in Multiple Myeloma: an in Vitro Study
2023
·
Raquel Alves
, Ana Sofia Almeida
, et al.
·
HemaSphere
Pb1910: Telaglenastat (cb-839) in Monotherapy and in Combination With Epigenetic Modulators or Ibrutinib Induces Cell Death in Chronic Lymphocytic Leukemia Cells
2023
·
Joana Jorge
, Hugo Santiago
, et al.
·
HemaSphere
P659: Buparlisib a Promising Therapeutic Approach in Chronic Myeloid Leukemia Resistant to Imatinib
2023
·
Raquel Alves
, Inês Silva
, et al.
·
HemaSphere
Pb1781: Therapeutic Potential of Dna Damage Response in Acute Myeloblastic Leukemia
2022
·
B. Lapa
, M. I. Costa
, et al.
·
HemaSphere
Pb1856: Demethylating Agents and Histone Deacetylase Inhibitors as New Therapeutic Strategies in Chronic Lymphocytic Leukemia
2022
·
J. Jorge #
, T. Gaspar #
, et al.
·
HemaSphere
Pb1782: Zinc in the Modulation of the Antiproliferative and Cytotoxic Effects of Olaparib in Acute Myeloid Leukemia
2022
·
M. I. Costa
, B. Lapa
, et al.
·
HemaSphere
Ps1014 Glycolysis Versus Oxidative Phosphorylation – Potential Therapeutic Targets in Aml
2019
·
B. Lapa
, J. Jorge
, et al.
·
HemaSphere
Metabolism as a therapeutic target in acute myeloid leukemic – Glycolysis or Oxidative phosphorylation
2019
·
Lapa, Beatriz Santos
·
Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
PDF
Show more works
View as search
Works count:
18
Citation count:
94
H-index:
4
I10-index:
4
Year
Topic
Type